32991-17-6

Basic information

• Product Name: BOC-LEU-GLY-OH
• Synonyms: BOC-LEU-GLY-OH;Boc-L-Leu-Gly-OH;N-(tert-Butoxycarbonyl)-L-leucylglycine;(S)-2-(2-((tert-Butoxycarbonyl)aMino)-4-MethylpentanaMido)acetic acid;N-[(1,1-Dimethylethoxy)carbonyl]-L-leucylglycine;tert-(Butyloxycarbonyl)leucylglycine;Boc-Leu-Gly-OH≥ 99% (TLC);(Tert-Butoxy)Carbonyl Leu-Gly-OH
• CAS NO: 32991-17-6
• Molecular Formula: C₁₃H₂₄N₂O₅
• Molecular Weight: 288.34
• Mol File: 32991-17-6.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 499.6±30.0 °C(Predicted)
• Appearance: /
• Density: 1.122±0.06 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 3.42±0.10(Predicted)
• CAS DataBase Reference: BOC-LEU-GLY-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-LEU-GLY-OH(32991-17-6)
• EPA Substance Registry System: BOC-LEU-GLY-OH(32991-17-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 32991-17-6(Hazardous Substances Data)

Usage

Description

BOC-LEU-GLY-OH, also known as N-[N-[(1,1-Dimethylethoxy)carbonyl]-L-leucyl]-glycine, is a white powder chemical compound with significant applications in the pharmaceutical industry. It is a synthetic peptide derivative that plays a crucial role in the development of various therapeutic agents.

Uses

Used in Pharmaceutical Industry:
BOC-LEU-GLY-OH is used as a building block for the synthesis of peptides, specifically aziridinedicarboxylic acid peptides, which serve as cysteine protease inhibitors. These inhibitors are essential in the development of treatments for various diseases, including cancer and inflammatory conditions.
BOC-LEU-GLY-OH is also used as a key component in the preparation of dipeptide monoester prodrugs of floxuridine. These prodrugs exhibit enhanced cancer cell growth inhibition, making them a valuable asset in the fight against cancer.

Upstream product

• 27610-07-7 (S)-methyl 2-(2-((tert-butoxycarbonyl)amino)-4-methylpentanamido)acetate 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 27532-96-3 glycine tert-butyl ester hydrochloride 
• 3392-09-4 Boc-Leu-ONSu 
• 66866-44-2 Boc-Leu-O-COO-isoBu 
• 283176-66-9 Boc-Leu-Gly-OAll 
• 56-40-6 glycine 
• 37783-45-2 Boc-L-Leu-Gly-OBzl 
• 51220-76-9 (N-(tert-butoxycarbonyl)-L-leucinyl)glycine ethyl ester 

Downstream Products

• 87251-43-2 Boc-Leu-Gly-D-Leu-Val-pNA 
• 87251-40-9 Boc-Leu-Gly-Pro-Val-pNA 
• 87263-11-4 Boc-Leu-Gly-Sar-Val-pNA 
• 87251-42-1 Boc-Leu-Gly-Gly-Val-pNA 
• 87251-41-0 Boc-Leu-Gly-Leu-Val-pNA 

Relevant articles and documents

Conformational studies on sequential polypeptides. Part V. Synthesis and characterization of (Pro Leu Gly)10, (Pro Leu Gly)(n) and (Leu Pro Gly)(n)

-

Metal- and Base-Free Room-Temperature Amination of Organoboronic Acids with N-Alkyl Hydroxylamines

We have found that readily available N-alkyl hydroxylamines are effective reagents for the amination of organoboronic acids in the presence of trichloroacetonitrile. This amination reaction proceeds rapidly at room temperature and in the absence of added metal or base, it tolerates a remarkable range of functional groups, and it can be used in the late-stage assembly of two complex units.

Synthesis and antitumor properties of the myelopeptide mp-1

The bone marrow-derived peptide Phe-Leu-Gly-Phe-Pro-Thr (MP-1) has been synthesized by the classical methods of peptide chemistry in solution, and its antitumor properties have been studied. It has been shown that MP-1 enhances the efficacy of the cytosta

Synthetic and cytotoxic and antimicrobial activity studies on annomuricatin B

The first total synthesis of annomuricatin B (8) is described via coupling of the tripeptide Boc-L-asparaginyl(benzhydryl)-L-alanyl-L-tryptophan-OH and the tetrapeptide L-leucyl-glycyl-L-thryl-L-proline-OMe followed by cyclization of the linear heptapeptide fragment. On pharmacological investigation, it was observed that the cycloheptapeptide 8 displays moderate cytotoxicity against Datton's lymphoma ascites and Ehrlich's ascites carcinoma cell lines with cytotoxic inhibitory concentration (50%) values of 11.6 and 14.1 μM, in addition to potent antidermatophyte activity against Trichophyton mentagrophytes and Microsporum audouinii with a minimum inhibitory concentration of 6 μg mL-1. Moreover, Gram-negative bacteria and Candida albicans were found to be moderately sensitive towards the newly synthesized peptide.